NewsBenzingaOcugen recibe aprobación provisional del regulador de Bahamas para OCU400 y se le ha concedido aprobación y designación prioritaria; la compañía suministrará OCU400 a través de un PEA, con el objetivo de tratar al primer paciente con RP en 90 días Ocugen recibe aprobación provisional del regulador de Bahamas para OCU400 y se le ha concedido aprobación y designación prioritaria; la compañía suministrará OCU400 a través de un PEA, con el objetivo de tratar al primer paciente con RP en 90 días Benzinga 2026.09.25 11:13 (GMT+0) Open on Benzinga Other news Lumen Technologies Intends To Switch Common Stock Trading From NYSE To Nasdaq, Effective Oct. 5 Under Same Ticker Stephens & Co. Maintains Overweight on CarMax, Raises Price Target to $74 This Tower Semiconductor Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday Barclays Initiates Coverage On Ligand Pharmaceuticals with Overweight Rating, Announces Price Target of $345 Raymond James Maintains Outperform on Axogen, Raises Price Target to $53 Jaguar Health Announces Issuance Of 182,091 Shares To Streeterville Capital For $1.67832M Reduction In 2021 Note Balance; 2025 Streeterville Note Fully Paid And Cancelled Following Exchange For 547,898 Shares
Lumen Technologies Intends To Switch Common Stock Trading From NYSE To Nasdaq, Effective Oct. 5 Under Same Ticker
This Tower Semiconductor Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Barclays Initiates Coverage On Ligand Pharmaceuticals with Overweight Rating, Announces Price Target of $345
Jaguar Health Announces Issuance Of 182,091 Shares To Streeterville Capital For $1.67832M Reduction In 2021 Note Balance; 2025 Streeterville Note Fully Paid And Cancelled Following Exchange For 547,898 Shares
